Bleeding

ImpactLife salutes longtime platelet donors on reaching major milestones

Retrieved on: 
Sunday, March 3, 2024
Collection, Bone marrow, Blood, Transplant, Army, Life, Health, Thrombocytopenia, Patient, Plateletpheresis, Bleeding, Trauma, Donor, Cancer, Medical device

Davenport, Iowa, March 03, 2024 (GLOBE NEWSWIRE) -- A pair of longtime platelet donors have reached significant donor milestones with ImpactLife, highlighting the importance of consistent donation patterns to meeting patient needs.

Key Points: 
  • Davenport, Iowa, March 03, 2024 (GLOBE NEWSWIRE) -- A pair of longtime platelet donors have reached significant donor milestones with ImpactLife, highlighting the importance of consistent donation patterns to meeting patient needs.
  • The nonprofit blood provider based in Davenport, Iowa, has approximately 6000 active platelet donors who have made at least one donation in the last two years.
  • He continued as a whole blood donor after returning from Vietnam, and recalls being asked to give platelet donation a try.
  • To help grow its base of platelet donors, ImpactLife is offering a $50 electronic gift card for those who donate platelets for the first or second time with ImpactLife.

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Retrieved on: 
Thursday, February 22, 2024
Online, Bleeding, Neoplasm, Blood, Shop, CCO, Health, Patient, Diagnosis, Colorectal cancer, DNA, Cancer, Partnership, Pharmaceutical industry

BERKELEY, Calif. and MAINZ, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is pleased to announce a distribution partnership with Praxisdienst, Germany’s largest online retailer for medical products.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is pleased to announce a distribution partnership with Praxisdienst, Germany’s largest online retailer for medical products.
  • This partnership will harness Praxisdienst's extensive distribution network alongside Mainz Biomed's leading-edge diagnostic technologies, ensuring broader access to their sophisticated medical solutions for healthcare professionals and patients throughout Germany.
  • Darin Leigh, CCO of Mainz Biomed, expressed enthusiasm about the partnership: "We are delighted to partner with Praxisdienst to distribute ColoAlert®, our innovative at-home screening test for colorectal cancer.
  • For more information about Mainz Biomed and our innovative products, please visit Mainz Biomed's website .

Evidence review: Maternal mental conditions drive climbing death rate in U.S.

Retrieved on: 
Wednesday, February 21, 2024
Mental health, Woman, PNP, Suicide, Infection, Prenatal development, Hospital, Public health, Bleeding, MPA, Fatality, Maternal death, Mental, DSM-IV codes, Pregnancy, Communication, Death, Internal bleeding, Risk, Health, JAMA Psychiatry, FACOG, University, Infant, Disease, Mother, White, Health policy, Maternal health, Child, Mortality, Drug overdose, George Washington University, Research, Medicine, Depression

“The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.

Key Points: 
  • “The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.
  • , associate chief of Perinatal Mental Health and member of the Center for Prenatal, Neonatal & Maternal Health Research at Children’s National.
  • Overdose and other maternal mental health conditions are taking the lives of more than twice as many women as postpartum hemorrhage, the second leading cause of maternal death.
  • Mental health conditions such as suicide or opioid overdose are to blame for nearly 23% of maternal deaths in America, according to reports from three dozen Maternal Morbidity and Mortality Review Committees, which are state-based organizations that review each maternal death within a year of pregnancy.

Herbal medicinal product: Lini semenArray, C: ongoing call for scientific data

Retrieved on: 
Tuesday, March 12, 2024
Key, Adolescence, Committee, Monograph, Paralysis, Plant, Date, Seed, Mouth, Constipation, Stomach, Safety, Allergy, Patient, Medicine, Constriction, Bleeding, Herbal medicine, Trial of the century, Ageing, Irritation, Water, Dietary supplement

Herbal medicinal product: Lini semenArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Lini semenArray, C: ongoing call for scientific data

Hemophilia B Pipeline Insight Report 2024: Comprehensive Analysis of Emerging Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024
Pharmaceutical, Health, Cardiology, Knowledge, Bleeding, Factor IX, Haemophilia B, Catalog, Genetic disorder, Research, Patient, Haemophilia, Pharmaceutical industry

The "Hemophilia B - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemophilia B - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
  • Significant advances in the treatment and management of Hemophilia B are forthcoming, according to a new comprehensive research publication now available on our website.
  • The global coverage within this report transcends geographical boundaries, providing a universal perspective on the research and development efforts aimed at combatting Hemophilia B.
  • The report elucidates the complexity of Hemophilia B diagnosis and underscores the importance of comprehensive blood coagulation tests.

Citizens for Judicial Fairness Launches Full Scale “BadFellas” Campaign to Expose Chancery Court Corruption and Abuse

Retrieved on: 
Wednesday, February 21, 2024
Professional Services, Courts, Publishing, State, Local, Small Business, Advertising, Communications, Legal, Media, Public Policy, Government, Advocacy Group Opinion, Court of Chancery, Corporate governance, Multimedia, Fraud, Goodfellas, University, Delaware Court of Chancery, Corruption, News, Bleeding, The, Supreme court

Today, Citizens for Judicial Fairness launched a new campaign, “BadFellas,” to expose Delaware Chancery Court injustices ahead of a University of Delaware Weinberg Center for Corporate Governance event featuring former Chancery Court Chancellor Andre Bouchard.

Key Points: 
  • Today, Citizens for Judicial Fairness launched a new campaign, “BadFellas,” to expose Delaware Chancery Court injustices ahead of a University of Delaware Weinberg Center for Corporate Governance event featuring former Chancery Court Chancellor Andre Bouchard.
  • The campaign will call out Bouchard, as well as former Supreme Court Chief Justice Leo Strine and current Chancery Court Chancellor Kathaleen McCormick, as “BadFellas” who are rigging Delaware’s court system and threatening the state's economy by driving businesses away from DE to incorporate in other states .
  • Citizens for Judicial Fairness released the following statement about the campaign, “The Chancery Court’s unchecked corruption and naked self-dealing is not just a perverse abuse of justice, it’s metastasized into an existential threat to the state’s economy as big companies incorporate elsewhere to escape the fraud and abuse.
  • The ‘BadFellas’ who run Delaware have spent years putting themselves and their cronies first at the expense of Delaware communities.

Does Iron Accumulate in Brain After Concussions?

Retrieved on: 
Thursday, March 7, 2024
Bangladesh Technical Education Board, Social media, Nervous system, Alzheimer's disease, Doctor of Philosophy, Concussion, Injury, Bleeding, Defense, Stroke, Annual general meeting, DSM-IV codes, Migraine, Multiple sclerosis, Parkinson's disease, History, Mayo Clinic, Clinical professor, Headache, Epilepsy, Brain, Research, Iron, American Academy, Medical imaging

The study involved 60 people who had post-traumatic headache due to mild traumatic brain injury, or concussion.

Key Points: 
  • The study involved 60 people who had post-traumatic headache due to mild traumatic brain injury, or concussion.
  • The people with mild traumatic brain injuries were matched with 60 people who had not had concussions or post-traumatic headache.
  • All the participants had brain scans to look at iron levels in various areas of the brain, using an indirect measure for iron burden.
  • "Previous studies have shown that iron accumulation can affect how areas of the brain interact with each other," Nikolova said.

Abbot's Adds the Whole Burger to Their Product Line of High-Quality Plant-Rich Foods

Retrieved on: 
Wednesday, March 6, 2024
Sprouts, Satiation, Bleeding, Plant, The Fresh Market, Meat, Food, Health, Whole Foods Market, Vitamin Cottage Natural Grocers, Ground beef, Allergen, Taste, Fast food

COSTA MESA, Calif., March 6, 2024 /PRNewswire/ -- Abbot's—a wellness company crafting delicious and versatile plant-rich products from real, wholesome ingredients—is taking the next step in their mission to spread the power of real, good food with the Whole Burger.

Key Points: 
  • The Whole Burger is designed to honor both your cravings and your well-being.
  • The Whole Burger is crafted with mushrooms, aromatic herbs, and savory spices to give it a flavorful, tender bite.
  • Whole Foods Market is the first retailer to carry Abbot's Whole Burger, which is now available nationwide in select stores.
  • "We recognize a growing interest in wholesome options within the plant-based community," says Kara Maloney, Category Merchant at Whole Foods Market.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on: 
Tuesday, March 5, 2024
Senior, Tenderness, Infection, Dizziness, AbbVie, XC, Lidocaine, Swelling, Exercise, Skin, Pregnancy, History, Cyst, Red, HIV/AIDS, Trial of the century, Allergy, Social media, Incidence, Neck, Dermatology, Aspirin, Pain, Forehead, Stroke, Hyaluronic acid, Pimple, Pigment, Ibuprofen, Scar, Rash, Anaphylaxis, Chin, Learning, Weakness, Safety, Filler (linguistics), DSM-IV codes, Hypoesthesia, Clinical trial, Paratriathlon, Bleeding, Face, Jaw, ABBV, Injection, Bruise, AMI, Inflammation, FDA, TSR, U.S. FDA, Confusion, Risk, Steroid, Patient, Tell, Wound, Gram, HIV, Cheek

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points: 
  • *1
    "The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
  • "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
  • The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
  • To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.

Hugel Receives FDA Approval in the United States of Letybo (letibotulinumtoxinA-wlbg) for Injection for the Treatment of Glabellar Lines

Retrieved on: 
Monday, March 4, 2024
Food and Drug Administration, Headache, MD, AB toxin, Catherine Disher, FDA, Blinking, Food, Vitamin, Dizziness, Hugel & Fils, Risk, Allergy, Human, Telecanthus, Rash, Patient, Skin infection, Child, Bleeding, Medication, Wheeze, Face, Pharmaceutical industry

NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults. In the coming months, Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the back half of 2024.

Key Points: 
  • NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults.
  • This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the U.S.," stated James Hartman, President, Hugel America.
  • Joely Kaufman, MD, commented, "The results from the clinical trials for letibotulinumtoxinA demonstrate efficacy, and a convincing safety profile in the treatment of glabellar lines1.
  • FDA approval is supported by positive results from three completed phase III trials that enrolled more than 1,000 subjects in the U.S. and Europe1.